MedTrace Logo

Remicade Safety Line (Ankylosing Spondylitis)(Study P03275)(COMPLETED)

NCT00818168 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 320

Last updated 2015-09-03

Study results available
· View outcomes & findings →

Summary

This observational study is in line with the German educational plan with the aim to implement a tool to increase and monitor the awareness of tuberculosis screening and to reinforce the patient eligibility for a treatment with Remicade according to the Summary of Product Characteristics (SmPc).

Conditions

  • Spondylitis, Ankylosing

Interventions

BIOLOGICAL

Infliximab

Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC)

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2010-12-31
Completion
2010-12-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00818168 on ClinicalTrials.gov